Clinical Trials Logo

LDL Cholesterol clinical trials

View clinical trials related to LDL Cholesterol.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05778656 Recruiting - LDL Cholesterol Clinical Trials

Cardiovascular Risk Prevention With a Mediterranean Dietary Pattern Reduced in Saturated Fat

CADIMED
Start date: March 19, 2023
Phase: N/A
Study type: Interventional

The Cardiovascular Risk Prevention With a Mediterranean Dietary Pattern Reduced in Saturated Fat (CADIMED) study is a randomized, controlled intervention trial aiming to develop a dietary intervention that promotes saturated fat (SFA) reduction through eliminating red and processed meat consumption and to evaluate its impact on lipid and cardiovascular disease (CVD) risk biomarkers. The main research question is: * Does lowering SFA intake from specific foods (e.g., red and processed meat) modify cardiovascular risk factors in a Mediterranean dietary pattern context? The aim is to compare, in a sample of 156 adult subjects (>18 years) with dyslipidemia, the effect of an intervention that promotes the elimination of red and processed meat intake vs. the control group that will follow the usual health advice for CVD prevention. Changes in CVD risk biomarkers, blood metabolomics and the microbiome will be investigated after 8 weeks of intervention.

NCT ID: NCT05765370 Recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)

Start date: March 24, 2023
Phase: N/A
Study type: Interventional

To determine whether treating to an LDL-C target of 25 to <70 mg/dL is superior to an LDL-C target of 70 to <100 mg/dL with respect to major cardiovascular events (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) in patients aged ≥75 years with atherosclerotic cardiovascular disease (ASCVD). To determine whether treating to an LDL-C target of 25 to <70 mg/dL is non-inferior to an LDL-C target of 70 to <100 mg/dL with respect to major safety events (hemorrhagic stroke, new-onset diabetes, muscle-related events, neurocognitive adverse events, new or recurrent cancer, cataract, or hepatic disorder [Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) >3× ULN, or total bilirubin >2× ULN]) in patients aged ≥75 years with ASCVD.